Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $8.3M
- Enterprise value
- $8.3M
- P/E (trailing)
- 0.2×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $8.50
- 52-wk low
- $0.24
- Beta
- —
- Shares out
- 10.1M
5-year trend
What this company does
ITEM 1. BUSINESS Overview We are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and by creating novel phage using synthetic biology, we develop phage-based therapies intended to address large-market diseases. Based on the urgency of treating the infection…
AI summary unavailable — showing raw filing excerpt
Generated from PHGE's filing dated 2026-02-19
Key risks
ITEM 1A. RISK FACTORS You should carefully consider the risks and uncertainties described below and the other information in this Annual Report before making an investment in our securities. Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our securities could decline and you could lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See “Cautionary Statement Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in…
AI summary unavailable — showing raw filing excerpt
Generated from PHGE's filing dated 2026-02-19
Profitability
Return on equity
-2780.3%
3887.3%Return on assets
626.0%
1426.6%Leverage
Debt / equity
-5.44×
788.5%Long-term debt / equity
1.75×
686.9%Debt / assets
122.5%
177.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $13.3M | +704.9% | — |
Q3 2025 2025-09-30 | — | — | $9.2M | +185.2% | — |
Q2 2025 2025-06-30 | — | — | $6.0M | +235.0% | — |
Q1 2025 2025-03-31 | — | — | $7.7M | -55.8% | — |
Q4 2024 2024-12-31 | — | — | $1.7M | — | — |
Q3 2024 2024-09-30 | — | — | $3.2M | -59.3% | — |
Q2 2024 2024-06-30 | — | — | $-4.5M | -169.7% | — |
Q1 2024 2024-03-31 | — | — | $17.3M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on PHGE — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$33.3M
Net activity
−$33.3M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PHGE
Institutional value
$110.1K
Total shares held
26.6K
Distinct holders
5
-6 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JPMORGAN CHASE & CO | 14.1K | $63.5K | +0 (+0.0%) | No change |
| 2 | JANE STREET GROUP, LLC | 11.8K | $44.4K | — | New |
| 3 | UBS Group AG | 573 | $2.2K | -1.7K (-74.9%) | Trimmed |
| 4 | SBI Securities Co., Ltd. | 20 | $75 | +0 (+0.0%) | No change |
| 5 | DANSKE BANK A/S | 1 | $4 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PHGE's latest filing finishes processing.